Initiation of therapy during the prodrome or erythema acyclovir cream stage was considered early, while therapy begun during the papule stage or later was considered late. In addition, Transport’s acyclovir cream product requires only one ten-minute application, compared with available formulations that require up to 5 daily applications for 4 to 5 days. This agent inhibits cells acyclovir cream 10 to 20 times longer than acyclovir does. Recommendations for clinical practice Topical 1% penciclovir cream applied every 2 hours while awake reduced the time to healing of sores, relief of pain, and cessation of viral shedding in patients with an episode of recurrent herpes labialis. Center for Disease Control and Prevention. Before much was known about how HSV is transmitted from mother to baby during birth, many pregnant women with the virus were given cesarean sections, regardless of when they became infected. The first patient has already been dosed, and the Company anticipates completing treatment in 2006. (2) This evidence supports early (prodrome or erythema stage) acyclovir cream but not late (macule, papule, vesicle, or crusted stage) treatment of HSV 1 with oral acyclovir. — Phase II Data Have Demonstrated Therapy Reduces Healing acyclovir cream time with a Single Treatment Transport Pharmaceuticals, Inc. The system consists of a reusable control unit and acyclovir cream disposable, single-use medicated cartridges. Overall, acyclovir did not effect lesion progression, size, or healing time to loss of hard crust or normal skin. Market research shows that, when asked to choose among products applied directly to the sore, many patients prefer a cream-based topical medication to ointments when treating cold sores. Unlike Acyclovir cream topical acyclovir, which is approved only for use in immunocompromised patients, topical penciclovir may be used in any adult with HSV labialis. However, Acyclovir cream the mean duration of pain for all patients significantly decreased (2. 5 days acyclovir cream vs 3. 8 days for placebo, P=. The study also has several secondary endpoints, one of which will measure the treatment’s ability to prevent full-blown lesions from occurring. For further information, please contact Ken Howling at 905-286-3000 or send inquiries to ir@biovail. There was no overall difference in the isolation of virus from patients in either treatment group.